[go: up one dir, main page]

MX2009011755A - Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. - Google Patents

Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.

Info

Publication number
MX2009011755A
MX2009011755A MX2009011755A MX2009011755A MX2009011755A MX 2009011755 A MX2009011755 A MX 2009011755A MX 2009011755 A MX2009011755 A MX 2009011755A MX 2009011755 A MX2009011755 A MX 2009011755A MX 2009011755 A MX2009011755 A MX 2009011755A
Authority
MX
Mexico
Prior art keywords
combination therapy
receptor inhibitor
adp receptor
compound acting
platelet adp
Prior art date
Application number
MX2009011755A
Other languages
English (en)
Inventor
Pamela B Conley
Patrick Andre
Uma Sinha
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2009011755A publication Critical patent/MX2009011755A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas y métodos para utilizar terapias de combinación que contienen [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2H-quinazolin-3-i l)-fenil]-5-cloro-tiofen-2-il-sulfonilurea, o una sal farmacéuticamente aceptable del mismo, para el tratamiento de enfermedades de trombosis.
MX2009011755A 2007-05-02 2008-05-02 Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. MX2009011755A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US91591107P 2007-05-03 2007-05-03
US94792107P 2007-07-03 2007-07-03
US97870007P 2007-10-09 2007-10-09
PCT/US2008/062561 WO2008137787A2 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor

Publications (1)

Publication Number Publication Date
MX2009011755A true MX2009011755A (es) 2010-02-12

Family

ID=39587017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011755A MX2009011755A (es) 2007-05-02 2008-05-02 Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.

Country Status (20)

Country Link
US (2) US20080279845A1 (es)
EP (2) EP2586439A1 (es)
JP (1) JP5439363B2 (es)
KR (1) KR101509829B1 (es)
CN (1) CN101686959B (es)
AU (1) AU2008247435A1 (es)
BR (1) BRPI0811000A2 (es)
CA (1) CA2684722A1 (es)
CO (1) CO6241105A2 (es)
EA (1) EA020045B1 (es)
EC (1) ECSP099775A (es)
ES (1) ES2467468T3 (es)
GT (1) GT200900283A (es)
IL (1) IL201826A (es)
MA (1) MA31396B1 (es)
MX (1) MX2009011755A (es)
NZ (2) NZ599556A (es)
PT (1) PT2146705E (es)
TN (1) TN2009000444A1 (es)
WO (1) WO2008137787A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001245353A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
BRPI0512273A (pt) * 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
DK2395002T3 (da) 2005-11-08 2014-09-08 Vertex Pharma Farmaceutisk sammensætning indeholdende en heterocyclisk modulator af ATP-bindende kassettetransportører
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
TW200813017A (en) 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
ATE544749T1 (de) 2006-11-02 2012-02-15 Millennium Pharm Inc Verfahren zur synthetisierung pharmazeutischer salze aus einem faktor-xa-hemmer
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
MX2009010953A (es) 2007-04-13 2009-10-29 Millenium Pharmaceuticals Inc Terapia anticoagulante en combinacion, con un compuesto que actua como un inhibidor del factor xa.
SG186638A1 (en) 2007-12-07 2013-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
AR074347A1 (es) * 2008-11-14 2011-01-12 Portola Pharm Inc Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso
CN102762550B (zh) 2009-12-17 2015-04-01 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
CA2785487C (en) * 2009-12-23 2017-11-28 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
CA2792993A1 (fr) * 2010-01-21 2011-07-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Composition particuliere pour son application comme medicament
EP2538925B1 (en) * 2010-02-25 2015-12-16 Bristol-Myers Squibb Company Apixaban formulations
CN106943403A (zh) 2010-04-07 2017-07-14 弗特克斯药品有限公司 药物组合物和其给药方法
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
MY161396A (en) * 2011-03-29 2017-04-14 Sanofi Sa Benzoic acid salt of otamixaban
US20150224091A1 (en) * 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
PL2806859T3 (pl) 2012-01-25 2019-11-29 Vertex Pharma Formulacje kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5- ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
US9708308B2 (en) 2012-12-19 2017-07-18 Merck Sharp Dohme Corp. Factor IXa inhibitors
US9914727B2 (en) 2012-12-19 2018-03-13 Merck Sharp & Dohme Corp. Factor IXa inhibitors
EP2934536B1 (en) * 2012-12-19 2017-09-27 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
EP3104702B1 (en) * 2014-02-11 2022-08-10 Merck Sharp & Dohme LLC Factor xia inhibitors
CN106831553A (zh) * 2015-09-11 2017-06-13 天津科伦药物研究有限公司 贝曲西班或其类似物的制备方法
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
EP3254674A1 (en) * 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
WO2018093695A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440147B1 (en) * 1998-09-03 2002-08-27 Rubicor Medical, Inc. Excisional biopsy devices and methods
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
EP1156803A4 (en) * 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
BR0014076A (pt) * 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
AU2001245353A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
AU2001296305B2 (en) 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
ZA200508481B (en) * 2003-04-09 2007-04-25 Japan Tobacco Inc Heteroaromatic pentacyclic compound and medicinal use thereof
AU2004279809B2 (en) 2003-10-03 2010-07-15 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
EP1678161B1 (en) * 2003-10-09 2009-12-30 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of factor xa
BRPI0512273A (pt) * 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2006045756A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
EP1844002A1 (en) 2005-02-02 2007-10-17 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
US7467697B2 (en) * 2005-10-07 2008-12-23 Ford Global Technologies, Llc Electromagnetic coupling device for engine accessories
ZA200804241B (en) * 2005-11-03 2009-09-30 Portola Pharm Inc [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quina-zolin-3-yl)-phenyl]-5-chlorothiophen-2-yl-sulfonylureas and forms and methods related thereto
CN102336702B (zh) 2005-11-08 2015-02-11 米伦纽姆医药公司 Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型
WO2007112367A2 (en) 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
TW200813017A (en) * 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
WO2008073670A2 (en) * 2006-12-08 2008-06-19 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
MX2009010953A (es) * 2007-04-13 2009-10-29 Millenium Pharmaceuticals Inc Terapia anticoagulante en combinacion, con un compuesto que actua como un inhibidor del factor xa.

Also Published As

Publication number Publication date
CN101686959B (zh) 2014-05-07
GT200900283A (es) 2011-10-05
NZ599556A (en) 2013-10-25
US20080279845A1 (en) 2008-11-13
EP2586439A1 (en) 2013-05-01
US8946219B2 (en) 2015-02-03
ES2467468T3 (es) 2014-06-12
ECSP099775A (es) 2010-01-29
WO2008137787A2 (en) 2008-11-13
WO2008137787A3 (en) 2009-02-05
MA31396B1 (fr) 2010-05-03
EP2146705A2 (en) 2010-01-27
HK1138765A1 (en) 2010-09-03
KR20100023836A (ko) 2010-03-04
CA2684722A1 (en) 2008-11-13
AU2008247435A1 (en) 2008-11-13
BRPI0811000A2 (pt) 2015-01-27
PT2146705E (pt) 2014-05-23
EP2146705B1 (en) 2014-03-05
JP5439363B2 (ja) 2014-03-12
JP2010526103A (ja) 2010-07-29
IL201826A (en) 2014-08-31
NZ581324A (en) 2012-05-25
IL201826A0 (en) 2010-06-16
EA200901442A1 (ru) 2010-06-30
EA020045B1 (ru) 2014-08-29
US20110033459A1 (en) 2011-02-10
TN2009000444A1 (en) 2011-03-31
KR101509829B1 (ko) 2015-04-06
CN101686959A (zh) 2010-03-31
CO6241105A2 (es) 2011-01-20

Similar Documents

Publication Publication Date Title
MX2009011755A (es) Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.
SG179418A1 (en) Inhibitors of the hedgehog pathway
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
JO2885B1 (en) Protein kinase inhibitors
ATE517882T1 (de) Chinolinderivate
MX2011009796A (es) Inhibidores de la cinasa pi3.
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
TW200806300A (en) New therapeutic combinations for the treatment of depression
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
IN2012DN02502A (es)
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
EA200700909A1 (ru) Азаиндолкарбоксамиды
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
PH12012501552A1 (en) Therapeutic or prophylactic agent for biliary diseases
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
IL195747A0 (en) Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity

Legal Events

Date Code Title Description
FG Grant or registration